Clinical evaluation of tigecycline in the treatment of nosocomial infections in a hospital in Taiwan

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 12, 2014, Pages 1030-1036

  Wu, Man Tzu Marcie ^a,b   Chen, Hsiang Yin ^a,b   Ou, Tsong Yih ^b   Kuo, Li Na ^a,b   Cheng, Kuei Ju ^a,b   Lee, Wen Sen ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Medication use evaluation; Nosocomial infections; Tigecycline

Indexed keywords

CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; COLISTIN; FOSFOMYCIN; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; AGED; APACHE; ARTICLE; BACTERIAL SUPERINFECTION; BURKHOLDERIA CEPACIA; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIDRUG RESISTANCE; NEOPLASM; OUTCOME ASSESSMENT; PNEUMONIA; PREDICTION; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SERRATIA MARCESCENS; SKIN INFECTION; STENOTROPHOMONAS MALTOPHILIA; TAIWAN; TEACHING HOSPITAL; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; CROSS INFECTION; MIDDLE AGED; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES;

EID: 84937562905     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202220     Document Type: Article

References (27)

1. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis. 2005;52:209-213.
2. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008;62(Suppl 1):i11-i16.
3. Tygacil. Philadelphia, PA: Wyeth Pharmaceuticals, 2010 (package insert).
4. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162-1172.
5. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834-844.
6. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963-1971.
7. FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010 September 1, [cited 3 August 2011]; Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
8. Prasad P, Sun J, Danner R, Natanson C. Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis. 2012;54:1699-1709.
9. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis. 2010;10:287.
10. Chemaly R F, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, Rolston K V, Raad II, Hachem RY. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore). 2009;88:211-220.
11. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother. 2009;63:775-780.
12. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, Byun MK. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J. 2012;53:974-984.
13. Poulakou G, Kontopidou F V, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Nicolaou C, Yphantis D, Antoniadou A, Trikka-Graphakos E, Roussou Z, Clouva P, Maguina N, Kanellakopoulou K, Armaganidis A, Giamarellou H. Tigecycline in the treatment of infections from multidrug resistant gram-negative pathogens. J Infect. 2009;58:273-284.
14. Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang C T, Lee MH. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect. 2011;63:351-361.
15. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis. 2006;43:389-390., author reply 389-390.
16. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis. 2007;26:793-800.
17. Lee N Y, Lee HC, Ko N Y, Chang CM, Shih HI, Wu CJ, Ko WC. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713-719.
18. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42:692-699.
19. Diekema DJ, Boots Miller BJ, Vaughn TE, Woolson R F, Yankey J W, Ernst EJ, Flach SD, Ward MM, Franciscus CL, Pfaller MA, Doebbeling BN. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis. 2004;38:78-85.
20. Lee K, Yong D, Jeong SH, Chong Y. Multidrugresistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J. 2011;52:879-891.
21. Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;40:332-336.
22. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob. 2009;8:18.
23. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect. 2002;8:144-153.
24. Choi J Y, Kim CO, Park YS, Yoon HJ, Shin S Y, Kim YK, Kim MS, Kim YA, Song YG, Yong D, Lee K, Kim JM. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia. Yonsei Med J. 2006;47:63-69.
25. García-Cabrera E, Jiménez-Mejías ME, Gil Navarro M V, Gómez-Gómez MJ, Ortiz-Leyba C, Cordero E, Pachón J; Hospitale Universitarios Virgen del Rocío. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis. 2010;29:867-871.
26. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy. 2007;27:1198-1201.
27. Martín-Gandul C, García-Cabrera E, Castillo-Ojeda E, Jiménez-Mejías ME. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates. J Antimicrob Chemother. 2012;67:1048-1049.